Meta-analysis presented at ENDO 2022 provides real-world evidence that a test can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules and that, when the test deems a nodule as suspicious, the patient’s risk of malignancy is consistent, and higher than that reported in the test’s original clinical validation (CV) study. Veracyte is...
New research of genetic testing for thyroid nodules shows that they can make a substantial difference in patient outcomes, not to mention eliminating the need for unnecessary surgeries and biopsies. Then why aren’t more patients choosing to be tested? Let’s face it: no one likes taking tests. Then again, no one particularly enjoys going under...
New pooled data from Phase 2 and Phase 3 clinical trials further reinforce that teprotumumab-trbw significantly improves proptosis (eye bulging) and diplopia (double vision) for thyroid eye disease (TED) in patients in different subgroups, with most maintaining a long-term response. The results were published recently in The Lancet Diabetes & Endocrinology. Teprotumumab-trbw is a fully human...
Small study finds 65% of patients taking teprotumumab report otologic symptoms. More patients than previously reported may experience hearing symptoms such as hearing loss or muffled hearing from a new treatment for thyroid eye disease TED), teprotumumab (Tepezza), according to a small study presented virtually at ENDO 2021. Teprotumumab, approved by the U.S. Food and...
Treatment should be individualized for common thyroid condition, researchers say Treatment of hypothyroidism, which results from an underactive thyroid gland, should be individualized and consideration should be given to alternatives to the first-line therapy, including desiccated thyroid extract and combination therapy to replace the body’s two main thyroid hormones, thyroxine (T4) and triiodothyronine (T3), according...
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to AZP-3601, Amolyt Pharma’s clinical candidate for the treatment of hypoparathyroidism. “We believe the FDA’s granting of Orphan Drug Designation to AZP-3601 reflects the agency’s recognition that new and more effective treatment options are needed for this serious endocrine disorder,” says Endocrine...
For the sixth year running, Endocrine News talks to editors from Endocrine Society publications to get the scoop on the top endocrine discoveries of 2020. In this fourth installment, we talk to The Journal of Clinical Endocrinology & Metabolism editors about what they think this year’s most significant studies were that will impact endocrine science...
While evidence-based guidelines don’t encourage it, many endocrinologists recognize a need to give combination therapy a trial in some patients with hypothyroidism. Although treatment guidelines specify levothyroxine as the standard of care for hypothyroidism, many thyroid specialists acknowledge a dirty little not-so-secret: When pressed by an insistent patient, many clinicians find it prudent to explore...
Endocrine News provides the latest news and research articles on thyroid conditions and treatment. For more info read this month’s issue of Endocrine News.
For the sixth year running, Endocrine News talks to editors from Endocrine Society publications to get the scoop on the top endocrine discoveries of 2020. In this fourth installment, we talk to The Journal of Clinical Endocrinology & Metabolism editors about what they think this year’s most significant studies were that will impact endocrine science...
